Key Driver Reshaping the Cannabi*s Pharmaceuticals Market in 2025: Increasing Epilepsy Cases Boost Demand For Cannabi*s-Based Treatments

What Are the Projections for the Size and Growth Rate of the cannabi*s** Pharmaceuticals Market?
The market size for pharmaceutical cannabi*s** has seen a considerable expansion recently. The market's value is predicted to enhance from $6.03 billion in 2024 to $9.45 billion in 2025, reflecting a compound annual growth rate (CAGR) of 56.66%. This significant surge during the historical period is largely due to the broader legalization of medical cannabi*s**, heightened understanding of the therapeutic advantages of cannabinoi*ds, an increase in the incidence of chronic and neurological disorders, favorable regulatory structures, increased investment in pharmaceuticals, and a shift in public outlook on the use of cannabi*s** in the healthcare sector.

In the coming years, the cannabi*s** pharmaceuticals market size is anticipated to witness remarkable growth, escalating to $56.37 billion in 2029 with a compound annual growth rate (CAGR) of 56.29%. The surge in the projection period can be credited to factors such as an increase in regulatory approvals, heightened awareness about the therapeutic advantages of cannabi*s**, wider uses in the management of pain and neurological disorders, a higher incidence of chronic diseases, advancements in drug delivery technologies, and the implementation of advantageous reimbursement policies. During the forecast period, key trends such as improvements in cannabinoi*d extraction methods, the introduction of targeted drug delivery systems, the use of synthetic cannabinoi*d preparations, enhancements in clinical trial approaches, and the incorporation of artificial intelligence in drug discovery are expected to arise.

What Are the Main Catalysts for Growth in the cannabi*s** Pharmaceuticals Market?
The anticipated growth in the cannabi*s** pharmaceuticals market is attributed to an increasing prevalence of epilepsy. Epilepsy is a neurologic condition marked by habitual, unprovoked seizures due to irregular neurological activity. The surge in epilepsy prevalence could be linked to improved diagnosis, enhanced awareness, and increased reporting, in addition to potential environmental, genetic, and lifestyle factors. cannabi*s** pharmaceuticals, through their utilization of cannabinoi*ds like cb*d, offer potential benefits in epilepsy management by decreasing seizure frequency and severity in patients who are resistant to conventional anti-epileptic drugs. For example, the European Brain Council, a nonprofit organization based in Belgium, noted in April 2022 that globally, there are over 600 neurological diseases and approximately 300 psychiatric conditions afflicting millions, including 65 million with epilepsy. Further, in July 2024, according to estimates by the Alzheimer Society of Canada, a health charity based in Canada, 771,939 Canadians are predicted to be living with dementia by the start of 2025, and this figure is expected to approach one million by 2030. Consequently, the escalating occurrence of epilepsy is fostering the expansion of the cannabi*s** pharmaceuticals market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

Which Businesses Are at the Forefront of cannabi*s** Pharmaceuticals Market Development?
Major companies operating in the cannabi*s** pharmaceuticals market are Curaleaf Holdings Inc., Aphria Inc., Green Thumb Industries Inc., Trulieve cannabi*s** Corp., Tilray Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc., Canopy Growth Corporation, Aurora cannabi*s** Inc., MedMen Enterprises Inc., OrganiGram Holdings Inc., Cronos Group, Enveric Biosciences Inc., Auxly cannabi*s** Group Inc., Valens Company Inc., Charlotte's Web Holdings Inc., Medical Marijuana Inc., Aleafia Health Inc., Supreme cannabi*s** Company Inc., Avicanna Inc., Emerald Health Therapeutics Inc.

How Is the cannabi*s** Pharmaceuticals Market Evolving?
The primary players in the cannabi*s** pharmaceuticals market are shifting their focus towards the creation of novel products, including advanced medical cannabi*s** formations, to treat various medical conditions and better patient outcomes. This encompasses specially crafted cannabi*s** products made for therapeutic usage, featuring exact doses of cannabinoi*ds such as THC* and cb*d. For example, in April 2024, Canexis Pharma AG, a pharmaceutical corporation based in Switzerland, was granted manufacturing and narcotics licenses from Swissmedic for cannabi*s** pharmaceuticals. These approvals permit the company to manufacture premium-grade medicinal components from cb*d and THC*, positioning Canexis to accommodate the growing demand for medical cannabi*s** domestically and internationally. By securing these licenses, the company exemplifies its adherence to severe regulatory standards, thereby boosting its reliability and capacity to participate in the fast-paced medical cannabi*s** market.

How Is the cannabi*s** Pharmaceuticals Market Segmented?
The cannabi*s** pharmaceuticals market covered in this report is segmented -

1) By Product Type: cannabinoi*d-Based Pharmaceuticals, cannabi*s** Extracts, Synthetic cannabinoi*ds
2) By Formulation Type: Capsules And Tablets, Oils And Tinctures, Topical Solutions
3) By Therapeutic Application: Cancer, Neurological Disorders, Pain Management
4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
5) By End-User: Hospitals And Clinics, Rehabilitation Centers, Research Organizations

Subsegments:
1) By cannabinoi*d-Based Pharmaceuticals: THC*-Based Pharmaceuticals, cb*d-Based Pharmaceuticals, Combination of THC* and cb*d Pharmaceuticals, Other cannabinoi*d-Based Formulations
2) By cannabi*s** Extracts: Full-Spectrum cannabi*s** Extracts, Broad-Spectrum cannabi*s** Extracts, Isolate cannabi*s** Extracts cb*d Isolate)
3) By Synthetic cannabinoi*ds: Synthetic THC* Analogues, Synthetic cb*d Analogues, Synthetic cannabinoi*d Receptor Agonists, Designer Synthetic cannabinoi*ds

Pre-Book Your Report Now For A Swift Delivery:
cannabi*s**-pharmaceuticals-global-market-report

Where Is the cannabi*s** Pharmaceuticals Market Growth Most Prominent?
North America was the largest region in the cannabi*s** pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabi*s** pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The cannabi*s** Pharmaceuticals Global Market Report?

- Market Size Analysis: Analyze the cannabi*s** pharmaceuticals Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the cannabi*s** pharmaceuticals Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall cannabi*s** pharmaceuticals market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the cannabi*s** pharmaceuticals market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20723

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.